Relay Therapeutics Inc. officer Donald Bergstrom filed a Form 144 notice on November 18, 2026, proposing the sale of 10,269 shares of common stock on NASDAQ under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Proposed sale: 10,269 shares of Relay Therapeutics common stock with an aggregate market value of $169,130.43.
  • Source of shares: Securities were acquired through Restricted Stock Units from the issuer, with vesting occurring between June 26, 2022, and July 27, 2023, according to the filing.
  • Prior sales in past 3 months: Bergstrom sold 2,252 shares on October 28, 2026, for gross proceeds of $41,932.24, and 8,530 shares on September 8, 2026, for gross proceeds of $161,775.72.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of October 30, 2025.
  • Total shares outstanding: 220,959,470 shares of common stock, as reported in the filing.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Bergstrom's Proposed Stock Sale at Relay Therapeutics: Filing Details

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Donald Bergstrom, identified as an officer of Relay Therapeutics Inc. (NASDAQ:RLAY), proposed to sell 10,269 shares of the company's common stock at an approximate date of November 18, 2026. The aggregate market value of the proposed sale is listed as $169,130.43. The filing identifies Morgan Stanley Smith Barney LLC Executive Financial Services as the named broker for the transaction.

The filing states that the securities to be sold "were acquired upon the vesting of restricted stock units during the period of 06/26/2022 through 07/27/2023," with the original acquisition date noted as June 26, 2022, and the nature of the acquisition listed as Restricted Stock Units granted by the issuer. The filing indicates the date of payment as June 26, 2022, with the nature of payment listed as "N/A."

In the section covering securities sold during the past three months, the filing discloses two prior transactions by Bergstrom: 2,252 shares sold on October 28, 2026, generating gross proceeds of $41,932.24, and 8,530 shares sold on September 8, 2026, generating gross proceeds of $161,775.72, both identified as 10b5-1 sales. The Rule 10b5-1 plan was adopted on October 30, 2025, according to the filing. Relay Therapeutics is headquartered at 60 Hampshire Street, Cambridge, Massachusetts 02139.

What Was Disclosed

The Form 144 notice discloses Relay Therapeutics officer Donald Bergstrom's proposed sale of 10,269 common shares valued at $169,130.43, acquired via vested restricted stock units, with the sale to be executed through a Rule 10b5-1 plan on NASDAQ.